Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects memory, cognition, and daily functioning.
According to the China Alzheimer’s Disease Report 2024, approximately 16.99 million people in China were living with Alzheimer’s disease and other forms of dementia in 2021. As populations age, disease management and long-term care are becoming increasingly important public health priorities.
On September 2, 2026, the National Medical Products Administration (NMPA) of China approved the subcutaneous autoinjector formulation of Leqembi® (lecanemab) for the initial treatment of early-stage Alzheimer’s disease.
Previously administered primarily through intravenous infusion, lecanemab now offers an additional subcutaneous delivery option, providing greater flexibility for eligible patients.
On October 22, 2026, the first prescription of this formulation was issued in the Boao Lecheng International Medical Tourism Pilot Zone in China, marking another step toward its clinical application.
Lecanemab is a monoclonal antibody targeting amyloid-beta (Aβ) aggregates. By reducing amyloid accumulation in the brain, it aims to slow cognitive and functional decline in patients with early-stage Alzheimer’s disease.
The development of subcutaneous autoinjection technology represents an important advancement in patient-centered drug delivery.
Key benefits include:
Automated Injection: Simplifies the drug administration process.
Time Efficiency: Injection takes approximately 15 seconds.
Home Administration Potential: Enables eligible patients to administer treatment at home following appropriate training and medical guidance.
Greater Flexibility: May reduce the need for frequent visits to healthcare facilities.
The combination of innovative medicines and advanced drug delivery devices is helping improve treatment accessibility and patient experience.
At NEST, we focus on advancing prefilled injection systems and automatic drug delivery devices to support pharmaceutical development and evolving administration needs.
Our Two-Step Automatic Injector Pen combines a prefilled syringe system with an automatic injection device, featuring:
Two-Step Operation: Simplifies the injection process and reduces handling steps.
Hidden Needle Design: Helps improve the user experience.
Automatic Needle Protection: The safety shield deploys and locks after injection, helping reduce accidental needlestick risks.
Anti-Roll Design: A square-shaped body helps prevent the device from rolling when placed on a surface.
Visual and Audible Feedback: Helps users identify injection progress and completion.
Available in four specifications:
0.5 mL
1.0 mL
2.25 mL
2.25 mL (High-Viscosity Version)
These options address different fill-volume and viscosity requirements, supporting diverse drug delivery applications.
From innovative drug development to advanced injection technologies, the pharmaceutical industry continues to explore more patient-centered treatment solutions.
NEST remains committed to the development of prefilled injection systems and automatic drug delivery devices, providing diverse product options to support pharmaceutical innovation and drug delivery.
NEST — Developing High-End Consumables and Building a Globally Recognized Brand.
